IntroductionTranscutaneous electrical nerve stimulation (TENS) is an electrotherapeutic procedure used for pain control that was first introduced to the medical community by Wall and Sweet in 1967 (Wall and Sweet, ). In 2012, the Center for Medicare Services rendered a decision stating as follows: ‘TENS is not reasonable and necessary for the treatment of CLBP [chronic low back pain]’ (cms.gov). Systematic reviews similarly conclude that TENS is ineffective or inconclusive for a variety of painful conditions (Khadilkar et al., ; Nnoaham and Kumbang, ; Dowswell et al., ; Kroeling et al., ; Rutjes et al., ; Walsh et al., ; Hurlow et al., ). On the other hand, Jauregui et al. () concluded in their systematic review that the treatment of chronic low back pain with TENS demonstrated significant pain reduction in patients who were treated for less than 5 weeks. Prior studies, however, have not considered important aspects of TENS treatment, namely intensity of stimulation and timing of assessment. We have previously suggested several factors may contribute to the equivocal findings in the literature on TENS effectiveness. These factors include dosing of TENS, timing of assessment, the population assessed and type of outcome (Sluka et al., ). Similarly, Bennett and colleagues describe significant biases in study design
European Journal of Pain – Wiley
Published: Jan 1, 2018
It’s your single place to instantly
discover and read the research
that matters to you.
Enjoy affordable access to
over 12 million articles from more than
10,000 peer-reviewed journals.
All for just $49/month
Read as many articles as you need. Full articles with original layout, charts and figures. Read online, from anywhere.
Keep up with your field with Personalized Recommendations and Follow Journals to get automatic updates.
It’s easy to organize your research with our built-in tools.
Read from thousands of the leading scholarly journals from SpringerNature, Elsevier, Wiley-Blackwell, Oxford University Press and more.
All the latest content is available, no embargo periods.
“Hi guys, I cannot tell you how much I love this resource. Incredible. I really believe you've hit the nail on the head with this site in regards to solving the research-purchase issue.”
Daniel C.
“Whoa! It’s like Spotify but for academic articles.”
@Phil_Robichaud
“I must say, @deepdyve is a fabulous solution to the independent researcher's problem of #access to #information.”
@deepthiw
“My last article couldn't be possible without the platform @deepdyve that makes journal papers cheaper.”
@JoseServera
$49/month
14-day Free Trial
$588
$360/year
14-day Free Trial
Read and print from thousands of top scholarly journals.
Already have an account? Log in
Bookmark this article. You can see your Bookmarks on your DeepDyve Library.
To save an article, log in first, or sign up for a DeepDyve account if you don’t already have one.